PureTech Health PLC (GB:PRTC)
LSE:PRTC
Want to see GB:PRTC full AI Analyst Report?
Earnings Data
Report Date
Aug 27, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
―Last Year’s EPS
-0.14Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented meaningful operational and clinical progress — notably positive Phase Ib data for Gallop (LYT‑200), Celea Phase IIb success and Phase III readiness, Seaport IPO momentum, improved operating loss and a confirmed runway through end‑2028 — while also acknowledging near‑term financial headwinds including a year‑over‑year cash decline, a swing to net loss driven by the absence of a one‑time 2024 gain, modest revenue, and the need for substantial external capital to fund late‑stage programs. Management emphasized capital discipline, earlier capitalization of founded entities, and intention to return cash to shareholders, but execution of financings (Celea, Gallop) and sensitivity to early product sales (Cobenfy) remain material risks.Company Guidance
Positive Gallop (LYT-200) Phase Ib Results
Top-line Phase Ib data showed an excellent safety profile (no dose-limiting toxicities or myeloid suppression), dose-dependent efficacy and identification of 12 mg/kg as the dose for next study. PureTech will prioritize relapsed/refractory high-risk MDS, plans FDA engagement for a potentially registration-enabling trial, and intends to seek majority third-party capital to fund next-stage development.
Celea deupirfenidone: Phase IIb Success and Phase III Readiness
Deupirfenidone demonstrated robust efficacy in Phase IIb with potential to replace SOC in IPF and is Phase III ready. Celea's fundraising is described as substantially complete (subject to negotiation) with target close early Q3 2026 to support the Phase III SURPASS‑IPF trial.
Seaport Progress and IPO Filing
Seaport filed a registration statement for a potential Nasdaq IPO; PureTech has increased reported stake (referenced ~42–43% vs prior ~35%), validating the hub-and-spoke model and demonstrating the ability to scale founded entities toward public markets.
Liquidity and Runway Affirmation
PureTech-level cash, cash equivalents and short-term instruments were $277.1M at end-2025 and unaudited cash as of March 31, 2026 was ~$248.1M. Management expects operational runway at least through end of 2028 (inclusive of planned participation in certain fundraisings).
Improved Operating Loss
Operating loss improved to $98.5M in 2025 from $136.1M in 2024 — a reduction of $37.6M (≈27.6%) — driven by lower G&A and R&D following Seaport deconsolidation and cost discipline.
Non‑dilutive Economics and Prior Monetizations
PureTech highlighted retained non‑dilutive economics (e.g., Cobenfy rights). Management has secured approximately $125M to date from a prior royalty sale and stated that monetization of founded entities has generated over $1B historically. Analyst-based projection of Cobenfy value to PureTech is ~ $160M through 2033 (not included in runway assumptions).
Strategic Refinement to Drive Capital Efficiency
Company announced strategic pillars: voluntary delisting from Nasdaq to reduce cost/administrative burden, earlier creation/capitalization of founded entities to improve return on capital, a refined innovation focus (targeting up to two development candidates over the next three years and progressing up to three concept-stage programs), and an intent to return a greater proportion of future cash generation to shareholders.
GB:PRTC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:PRTC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2026 | 130.00 p | 124.60 p | -4.15% |
Aug 28, 2025 | 134.00 p | 126.60 p | -5.52% |
Apr 30, 2025 | 125.80 p | 123.00 p | -2.23% |
Aug 28, 2024 | 165.00 p | 169.60 p | +2.79% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does PureTech Health PLC (GB:PRTC) report earnings?
PureTech Health PLC (GB:PRTC) is schdueled to report earning on Aug 27, 2026, TBA (Confirmed).
What is PureTech Health PLC (GB:PRTC) earnings time?
PureTech Health PLC (GB:PRTC) earnings time is at Aug 27, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of PureTech Health PLC stock?
The P/E ratio of PureTech Health is N/A.
What is GB:PRTC EPS forecast?
Currently, no data Available